The dual agonist of GLP-1 and glucagon, developed in partnership with Zealand Pharma, achieved a biopsy-assessed improvement in MASH, without worsening of fibrosis (scarring), in up to 83% of ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

NPR's Up First is the news you need to start your day. The three biggest stories of the day, with reporting and analysis from NPR News — in 10 minutes. Available weekdays at 6:30 a.m. ET ...

MASH is a severe form of nonalcoholic fatty liver disease where excess fat in the liver causes inflammation. About 5% of U.S. adults have MASH (short for metabolic dysfunction-associated ...

April 11, 2025 • China retaliated against the imposed U.S. tariffs with a hefty 125% tariff on U.S. goods. And, how people on college campuses feel about free speech since President Trump has ...

Found the Volkswagen Up of your dreams? Now you want to know all about it! With the help of Parkers, you can find out all of the key specs about the Volkswagen Up from fuel efficiency in MPG and top ...